Outcomes of Clostridium difficile infection in hospitalized leukemia patients: a nationwide analysis
- PMID: 25801085
- DOI: 10.1017/ice.2015.54
Outcomes of Clostridium difficile infection in hospitalized leukemia patients: a nationwide analysis
Abstract
BACKGROUND The incidence of Clostridium difficile infection (CDI) has increased among hospitalized patients and is a common complication of leukemia. We investigated the risks for and outcomes of CDI in hospitalized leukemia patients. METHODS Adults with a primary diagnosis of leukemia were extracted from the United States Nationwide Inpatient Sample database, 2005-2011. The primary outcomes of interest were CDI incidence, CDI-associated mortality, length of stay (LOS), and charges. In a secondary analysis, we sought to identify independent risk factors for CDI in leukemia patients. Logistic regression was used to derive odds ratios (ORs) adjusted for potential confounders. RESULTS A total of 1,243,107 leukemia hospitalizations were identified. Overall CDI incidence was 3.4% and increased from 3.0% to 3.5% during the 7-year study period. Leukemia patients had 2.6-fold higher risk for CDI than non-leukemia patients, adjusted for LOS. CDI was associated with a 20% increase in mortality of leukemia patients, as well as 2.6 times prolonged LOS and higher hospital charges. Multivariate analysis revealed that age >65 years (OR, 1.13), male gender (OR, 1.14), prolonged LOS, admission to teaching hospital (OR, 1.16), complications of sepsis (OR, 1.83), neutropenia (OR, 1.35), renal failure (OR, 1.18), and bone marrow or stem cell transplantation (OR, 1.27) were significantly associated with CDI occurrence. CONCLUSIONS Hospitalized leukemia patients have greater than twice the risk of CDI than non-leukemia patients. The incidence of CDI in this population increased 16.7% from 2005 to 2011. Development of CDI in leukemia patients was associated with increased mortality, longer LOS, and higher hospital charges.
Similar articles
-
The burden of Clostridium difficile in surgical patients in the United States.Surg Infect (Larchmt). 2007 Dec;8(6):557-66. doi: 10.1089/sur.2006.062. Surg Infect (Larchmt). 2007. PMID: 18171114
-
Association of Clostridium difficile infection with outcomes of hospitalized solid organ transplant recipients: results from the 2009 Nationwide Inpatient Sample database.Transpl Infect Dis. 2012 Oct;14(5):540-7. doi: 10.1111/j.1399-3062.2012.00761.x. Epub 2012 Jun 22. Transpl Infect Dis. 2012. PMID: 22726461
-
Prevalence of Clostridium difficile infection presenting to US EDs.Am J Emerg Med. 2015 Feb;33(2):238-43. doi: 10.1016/j.ajem.2014.11.023. Epub 2014 Nov 26. Am J Emerg Med. 2015. PMID: 25488337
-
Comorbidities, Exposure to Medications, and the Risk of Community-Acquired Clostridium difficile Infection: a systematic review and meta-analysis.Infect Control Hosp Epidemiol. 2015 Feb;36(2):132-41. doi: 10.1017/ice.2014.39. Infect Control Hosp Epidemiol. 2015. PMID: 25632995 Review.
-
A systematic review of Clostridium difficile infection following reversal of ileostomy.Colorectal Dis. 2017 Oct;19(10):881-887. doi: 10.1111/codi.13873. Colorectal Dis. 2017. PMID: 28872758 Review.
Cited by
-
Clostridioides difficile Toxins: Host Cell Interactions and Their Role in Disease Pathogenesis.Toxins (Basel). 2024 May 24;16(6):241. doi: 10.3390/toxins16060241. Toxins (Basel). 2024. PMID: 38922136 Free PMC article. Review.
-
Host Immune Responses to Clostridioides difficile Infection and Potential Novel Therapeutic Approaches.Trop Med Infect Dis. 2023 Nov 23;8(12):506. doi: 10.3390/tropicalmed8120506. Trop Med Infect Dis. 2023. PMID: 38133438 Free PMC article. Review.
-
Host Immunity and Immunization Strategies for Clostridioides difficile Infection.Clin Microbiol Rev. 2023 Jun 21;36(2):e0015722. doi: 10.1128/cmr.00157-22. Epub 2023 May 10. Clin Microbiol Rev. 2023. PMID: 37162338 Free PMC article. Review.
-
Clinical outcomes of antimicrobial resistance in cancer patients: a systematic review of multivariable models.BMC Infect Dis. 2023 Apr 18;23(1):247. doi: 10.1186/s12879-023-08182-3. BMC Infect Dis. 2023. PMID: 37072711 Free PMC article.
-
Host Immune Responses to Clostridioides difficile: Toxins and Beyond.Front Microbiol. 2021 Dec 21;12:804949. doi: 10.3389/fmicb.2021.804949. eCollection 2021. Front Microbiol. 2021. PMID: 34992590 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
